Genprex, Inc. · NASDAQ:GNPX
Genprex — Investor Presentation (January 2026)
64 slides from Genprex's investor presentation, Jan 7, 2026
Slide 1: Pioneering Gene Therapies for Patients in Need
a) Genprex’ Pioneering Gene Therapies for Patients in Need January 2026
Slide 2: Forward-Looking Statements
O Gen; Forward-Looking Statements Stents contained th pee eging mache ae notte acs ae “Trwarsoching stoners wih the meaning oft rke Sess Ligaen elm ALOE 1955 because chstatarets ar jee rksanauncr ates seul eas me awry fomttose epreseder pied by sth fewer ding toes So LenS ‘nda Butare atte sera regar
Slide 3: Our Mission
Our Mission Advancing novel gene therapies for patients afflicted with cancer or diabetes. © Genprex
Slide 4: Program Highlights
Program Highlights ONCOLOGY DIABETES @® Non-viral gene therapy platform @® Addressing both Type 1 and Type 2 diabetes with AAV gene therapy Novel approach using systemic gene therapy to replace tumor suppressor genes for cancerin __ (@) Novel infusion process delivers genes to pancreas humans Demons
Slide 5: Research and Development Pipeline
Research and Development Pipeline sec Accloim:5 'sttanoo|
Slide 6: Oncology
Q ONCOLOGY REPROGRAMMING THE COURSE OF CANCER ceo www.genprex.com
Slide 7: Why TUSC2?
Why TUSC2? Discovery —— Tumor Suppressor Candidate 2 ——~ [Chromosome 3p213 deleted ne — Previously called FUS1 ——e NPRL2 is in the same area of the chromosome © Genprex Tumor Suppressor Gene TUSC2 restoration in cancer cells in vitro inhibits cell growth and induces apoptosis TUSC2 is encoded by nuc
Slide 8: Tumor Suppressor Genes Deleted During Cancer Development
Tumor Suppressor Genes Deleted During Cancer Development ——~ Tumor suppressor genes are deleted early during cancer development + 82% of all non-small cell ung cancers and 100% of all small-cell lung cancers express decreased amounts of TUSC2 ‘tumor suppressor protein ——# Loss or reduction of TUSC2
Slide 9: Oncoprex Delivery System
Oncoprex® Non-viral, positively-charged lipid-based nanoparticle in a lipoplex form is systemically Delivery System delivered. NON-VIRAL DELIVERY OF ‘TUMOR SUPPRESSOR GENE © Genprex: Cationic lipoplex carries drug to tumors.
Slide 10: Our Cancer Treatment Approach
Our Cancer Treatment Approach Tumor suppressor genes are deleted early during cancer development. Our method of treating cancer is to reintroduce tumor suppressor genes to patients. © Genprex ‘Tumor Suppressor Gene in a DNA Plasmid, We haverrights to pressor genes that may. Nanoparticles in a Lipopl
Slide 11: Novel Platform to Treat Cancer
Novel rlatforn to adc eecreectuerecy ston reat Cancer Genes Allows for delivery of TUSC2 and NPRL2 ‘genes and potentially a variety of other genes, Synergies Can be used in combination with other cancer therapies Such as Tagrisso® and Tecentria® Cancers Could combat multiple cancers including NSCLC,
Slide 12: Regorsa Targets Cancer At Its Core
Regorsa® Targets Cancer At Its Core | <> Controls Cell Signaling Tyrosine kinase inhibition decreases cancer cell proliferation © Genprex Stimulates Apoptotic Pathways Leads to programmed cancer cell death Multiple anti-cancer mechanisms of action. Oe) Modulates Immune Response Promotes immune activ
Slide 13: Regorsa Reduces Glycolysis in Cancer Cells
Regorsa® Reduces Glycolysis in REQORSA Reverses Fundamental Cancer Cells Characteristic of Cancer Cancers are detected by PET scans + PET scanning is based on increased glucose uptake in cancer cells + Due to high rate of glycolysis in cancer cells Increased glycolysis is found in virtually all canc
Slide 14: Lung Cancer: By the Numbers
Lung Cancer: By the Numbers 124K $48B 27% e e e e U.S. Annual Global Lung Global U.S. Lung U.S. Average Mortality Cancer Incidence Market Cancer Incidence Lung Cancer Survival Globalmarket Isprojected More than 226,000 new Rate {to grow from $18.3 billion in he ung cancer five-year 2018 to $487 illo
Slide 15: Regorsa Monotherapy ONC-001 Trial
Regorsa® Monotherapy ONC-001 Trial DOSE ESCALATION STUDY Explored toxicity and tolerability in patients. . . j Phase 1 monotherapy results 5 + 31 Stage IV lung cancer patients + 0.01-0.09 mg/kg + 23 patients evaluable + 5 patients had stable disease + 2patients had tumor shrinkage + Generally well-t
Slide 16: Selective Uptake of Regorsa
Selective Uptake REQORSA Targets Cancer Cells of Reqorsa Pretreatment Biopsies Posttreatment Biopsies REQORSA usc? ncer cells while ‘minimizing its uptake by norm: Patient 1 (o2molks) Patient 2 (06 mg/g) © Genprex
Slide 17: Regorsa + Tarceva ONC-002 Phase 1/2 Trial
Regorsa® + Tarceva ONC-002 Phase 2 Trial Met Simon 2-stage criteria to enroll the full 39 subjects, but was discontinued to start study with Tagrisso. © Genprex soe sowe toe
Slide 18: Drug resistance to Tagrisso and Tecentriq is inevitable
For most patients, drug resistance to Tagrisso® and Tecentriq® is inevitable.1.23 Our approach is designed to address drug resistance. © REQORSA Immunogene Therapy may be complementary with targeted drugs and immunotherapies. © REQORSA's multimodal activity may block emerging bypass pathways, thereb
Slide 19: AACR 21: Regorsa + Tagrisso
AACR 21: Regorsa® + Tagrisso Reduce Tumor Growth in Tagrisso Resistant Tumors = Enhanced Anti-Tumor Activity REQORSA in combination with 2 Tagrisso demonstrated significantly increased anti-tumor efficacy in EGFR mutant Tagrisso resistant NSCLC tumors in H1975- ‘OsiR mouse xenografts. Teor oie nn) ©
Slide 20: Acclaim-1 Trial
teney af o FDA Fast Track Designation * oer Acclaim -1 e Phase 1 Dose Escalation: 12 patients (completed) Regorsa® in combination with AstraZeneca's Tagrsso® fer NSCLC Phase 2b: Comp: ing Progression Free Survival of REQORSA + Tagrisso ve. Platinum-Based Chemotherapy H ; A REQORSA* + TAGRISSO © Genp
Slide 21: Phase 1 Dose Escalation
Phase 1 Dose Escalation SSE ea ES Medan oe inene) $915060 S186) 8957.7 5968.70) Progression Free Survival by Dose Group PFS aye) {eternon operat sow kre cama nt ye ar ree wr tw PFS ‘nr sya ongng Part wing rons © Genprex Excellent safety profile and efficacy in relapsed patients. Delayed Infusion-Rel
Slide 22: Regorsa in Small Cell Lung Cancer
Regorsa® in Small Cell Lung Cancer Targeting Small Cell Lung Cancer (in addition to NSCLC} allows Genprex to address virtually the entire lung cancer market. ‘Small Cell Lung Cancer: ——— Consistently has low TUSC2 protein levels — Documented to often have deletion of at least one TUSC2 gene allele.
Slide 23: SCLCs Express Low Levels of TUSC2 Protein
SCLCs Express Low Levels Of TUSC2 Protein IHC analysis of tumor specimens Since all SCLCs have reduced or no TUSC2 —_—— 41% of SCLC have no TUSC2 protein expression protein expression, re-expressing TUSC2 100% of SCLC have reduced or no TUSC2 protein protein may lead to clinical efficacy. expression
Slide 24: Atezolizumab (Tecentriq) SCLC Approval Trial
Atezolizumab (Tecentriq®) SCLC Approval Trial IMpower133 Study Adding Tecentriq to standard therapy improves survival in SCLC and establishes a new standard therapy for ES-SCLC. —— Untreated, extensive stage SCLC ——~ Carboplatin & etoposide chemotherapy + atezolizumab or placebo + A cycles, then ate
Slide 25: Atezolizumab Maintenance Therapy
Atezolizumab Maintenance Therapy Once patients begin maintenance therapy with Tecentriq, Progression Free Survival is very short (2.6 mos) ——— Atezolizumab vs placebo + AILCR, PR, and SD patients received maintenance therapy + Endpoints measured from the start of maintenance therapy ——° PFS 2.6 vs 1
Slide 26: Regorsa Adds Significantly to Tecentriq Treatment
Regorsa® Adds Significantly to HE42 SCLC cell xenografts Tecentriq Treatment in humanized mice CONTROL REQORSA REQORSA + Atezo on H841 SCLC ‘Lung Met in Humanized Mice e003 TECENTRIQ hoe he © Genprex
Slide 27: Increased Immune Response with Regorsa and Tecentriq
Increased Immune Response with Regorsa® and Tecentriq © Genprex
Slide 28: Acclaim-3 Trial
© Patients with ES-SCLC whe aid not develop tumor progression 1 after receiving Tecentrig® and chemotherapy oT Fes ack Detgnaton ang OtanOtus Desenatn Acclaim -3 © ~62 patients ‘© Phase 1 Dose Escalation: (completed) © Phase 2: ~50 patients (currently enrolting) ‘2 Phase 2 interim analysis after 25t
Slide 29: Regorsa in Ras Inhibitor Resistant Lung Cancer
Regorsa® in Ras Inhibitor Resistant Lung Cancer 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics + TUSC2 transfection significantly reduced colony fermation in two Acquwed Resistant (AR) cell tines + Transfection of TUSC2 also markecly creased apoptosis in AR cells + Treetm
Slide 30: Regorsa in ALK-EML4 Positive Translocated Lung Cancer
Regorsa® in ALK-ELM4 Positive SRA with The University of Michigan Rogel Cancer Center Translocated Lung Cancer and Collaboration with ALK- Positive Advocacy Group 2024 AACR Annual Meeting: ALK-Positive Collaboration: REQORSA induced apoptosis in alectinib resistant EML4-ALK positive NSCLC cell ties
Slide 31: Reqorsa in ALK Xenograft Model
Reqorsa® in ALK Xenograft Model REQORSA markedly decreases growth of ALK- sensitive xenografts in mice * Both as single agent and in combination with alectinib Regorsa + vehicle control BNP + alectinib 60.14 Regorsa + alectinib, 78.60 © Genprex NCI-H2228 xenograft ays ent eee cet +
Slide 32: Regorsa in Mesothelioma
Regorsa® in Mesothelioma 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics + Researchers investigated whether + Researchers demonstrated that TUSC? transfection could modulate REQORSA treatment resulted in: MPM aggressive properties + Significant decrease in cell + Four MPM
Slide 33: NPRL2 Induces Anti-tumor Activity in NSCLC
NPRL2 Induces wei2Punrs an ASI Lang Met Anti-tumor Activity in NSCLC Further Evidence of Oncoprex® Delivery System as a Platform for Treatment Using Tumor Suppressor Genes i. ice were treated with NPRLZ gene therapy, a é FA the combination é N= 10-11 micelroup 0 Study investigated the antitumor resp
Slide 34: Combined TUSC2 and NPRL2 Re-Expression in SCLC
Combined TUSC2 and NPRL2 Re-Expression in SCLC H841 lacks both TUSC2 and NPRL2 protein Increased control of xenograft growth compared to: + Control + TUSC2 re-expression alone + NPRL2 re-expression alone © Genprex Tumor Volume (mm?) TUSC2+NPRL2 Dual Gene Therapy Combination on Inflamed. H841 Tumors
Slide 35: Diabetes
Q DIABETES
Slide 36: Diabetes: By the Numbers
Diabetes: By the Numbers 38M S966B $24B e e e e Diabetes US. Diabetes Global? Global Diabetes T2D Global Market _T1D Global Market Prevalence Prevalence Expenditures (6.7% CAGR‘) (17.2% CAGR') 1u ed tor
Slide 37: Diabetes can cause serious complications
Diabetes can cause serious complications. In 2021, there was approximately 1 death every 5 seconds caused by diabetes worldwide. Genprex
Slide 38: Diabetes Causes Serious Complications
Diabetes Causes Serious Complications Heart Disease Leading cause of death for men and women in US. Diabetics are 2x as likely o have heart disease or a stroke. Chronic Kidney Disease ‘Approximately 1n3 aduks with dlabetes have CKO. Kidney dlseases ae the Sth leading cause of death in US. Nerve Dama
Slide 39: Diabetic Patients Are In Need of Advanced Therapy
Diabetic Patients Are In Potential for disease modification Need of Advanced Therapy for long-term effectiveness. s Patients suffer compromised quality of life Gare kee Despite certain advancementsin treatment, qualty produceinsuin and oNAteahmigue fife remains highly compromise for many es i ‘ Indd
Slide 40: Novel Gene Therapy Collaboration with University of Pittsburgh
Novel Gene Therapy Collaboration with University of Pittsburgh Diabetes Program intends to address both T1D and T2D. 38M or 11.6% of Americans Have Diabetes* Type 1 Diabetes (5-10%) ——e Type 2 Diabetes (90-95%) fn autosmmune condion where the bodys Inabityof tre pancreas to produce enaugh immune sys
Slide 41: GPX-002 Replenishes Insulin Producing Cells
GPX-002 Replenishes B . : ‘eprograms and restores Insulin Producing Cells cell function in T1D. Delivers Genes to the Pancreas A novelintusion process uses dx + Hypereycemia Z Evghyemia Intraductal infusion of Pk: and Mofo: expressing AAV == ‘Alpha: to beta-cell ‘reprogramming Reprograms Alpha Cells
Slide 42: Reversed Drug-Induced Diabetes in T1D Mouse Model
Reversed Drug-Induced Diabetes in T1D Toxin-Induced Mouse Model ———* _ Reprogramed alpha cells into beta-like cells that appropriately produce insulin in response to glucose levels. — Normalized blood glucose in beta cell-toxin-induced diabetic mice. © Genprex
Slide 43: Restored Blood Glucose in T1D Autoimmune Mouse Model
Restored Blood Glucose in T1D In Autoimmune Mouse Model for Four Months The duration of restored blood glucose levels in mice could potentially translate to decades in humans. © One week in a mouse tends to beta cal ass (ng) | | : correlate to about one year in humans © NOD mice given syngeneic isle
Slide 44: Induced Generation of Functional Insulin-Expressing Cells from Alpha Cells
Induced Generation of Functional Insulin-Expressing Cells from Alpha Cells in Human Islets Provides a potential basis for further investigation in human Type 1 diabetes © Human istets treated with to destroy beta-cells, th either AAV-PM or AAV-GFP «AAV treated islets then transplanted into hyperatyc
Slide 45: Non-Human Primate Model of T1D
Non-Human Primate Model of T1D Reduced Insulin Requirements © Genprex or NAPA im desl ul li hl NHP 2 insubin (Car iio ca Data from University of Pittsburgh researchers show a marked reduction in insulin requirements. Virat infusion is 72 wall
Slide 46: Decreased Insulin Requirements and Improved Glucose Tolerance in NHPs
Decreased Insulin Requirements and Improved Glucose Tolerance in NHPs Following the pancreatic intraductal infusion of the AAV ‘engineered construct, the eight NHPs had e ‘Decreased insulin requirements 0001) © Increased c-peptide levels (p<0.05) © Improved glucose tolerance compared to baseline (p<
Slide 47: NHP2 Three-Month Glucose Tolerance Test
NHP2 Three-Month Glucose Tolerance Test © Genprex
Slide 48: IHC Eight Weeks After Gene Therapy
IHC Eight Weeks After Gene Thera py Need at least 20% of normal beta cell mass to maintain normoglycemia Normal NHP IP Without Gene Therapy Diabetic NHP After Ger Genprex
Slide 49: Rejuvenates Exhausted Beta Cells in T2D NHP Models
Rejuvenates Exhausted Beta Cells in T2D NHP Models NHP 1 NHP 2 ‘AAV infusion into the pancreatic duct Direct pancreas injection At three months, NHP displayed int improvements in glucose Improved glucose tolerance testing over several months Qr At seven months, NHP had normal glucose tolerance testi
Slide 50: Studying GPX-002 Using a Lipid Nanoparticle Non-Viral Delivery System
Studying GPX-002 Using a Shows Potential for Re-Dosing Using Lipid Nanoparticle Non-Viral Delivery System New studies use an alternative second generation approach with a non-viral lipid nanoparticle delivery system | First and only company to research diabetes gene therapy using a lipid nanoparticl
Slide 51: Corporate
Q CORPORATE www.genprex.com
Slide 52: Our Team: Company Management
Our Team: Company Management % # Marks. Berger, MO Thomas Gallagher, JD Presiden, chi recive Oca & hi Masia Fico : Chet Ponca Ofcee Dsvid Senloss, JD ehoag tant
Slide 53: Our Team: Scientific Advisory Board
Our Team: Scientific Advisory Board Tony $ K Mek Pas Antero inne George Simon George K Gittes
Slide 54: Our Team: Clinical Advisory Board
Our Team: Clinical Advisory Board
Slide 55: Our Team: Board of Directors
Our Team: Board of Directors
Slide 56: Achievements & Upcoming Milestones
Achievements & Upcoming Milestones Acclaim -1 Acclaim -3 GPX-002 Corporate © Genprex
Slide 57: We believe in a future of transformational patient care
We believe in a future of transformational patient care. 21 Century Large Combination Two FDA Exploring New Gene Markets & | Trials with Top | Fast Track Indications & Therapies Unmet Need | SellingDrugs | Designations | Partnerships
Slide 58: Slide 58
Slide 59: Research References
Research References Slide 7 1. Wasubo Behrens G Vrman! AK; eal High resoludan chromosome 3p looping of human long cancer and preneoplasccpresvasive bronchial épiielum reveals mulope,dscononvous Stes ofp alle ossand three reglons of requencbreakpoines. Cancer Res 2000;60741949-1960, Slide 8 1. Maobo
Slide 60: Research References
Research References Slide 35 Cencersfor Disease Conca: uso ldacea Incemscona Babee: Federston: ame auch TOF Dapetes Ads: ans aakecum Research and Nore fue LSS ‘Global Dora hams au awe Slide 36 1. DF Dabeces Atos: msc ya Slide 37 1. Gencersfor Disease Conero bn aa Tati, 2. smpucadon reversion Ceeers
Slide 61: Appendix
Q APPENDIX www.genprex.com
Slide 62: Regorsa + Keytruda Significantly Reduced Tumor Growth
® ® REQORSA increases immune response Regorsa® + Keytruda iss s Significantly Reduced Tumor Nailed Growth REQORSA + Keytruda® ‘The independent immunologic effects of REQORSA and Keytruda markedly decrease tumor growth by increasing the immunologic attack on the tumor compared to PD-1 inhibition alon
Slide 63: AACR 21: Reqorsa May Enhance First-Line Standard of Care
AACR 21: Reqorsa® May Enhance First-Line Standard of Care Reqorsa® + Keytruda® + Chemo negonen chemo-immunotherepy on KRAS-LKB1 . {KL}-mutant lung metastases in humanized mice. ——— Triple combination demonstrates “ = : 4 4 ee ae oe oe Ata robust antitumor immunity in K- pater arena fo trutant NSCLC
Slide 64: Acclaim-2 is no Longer enrolling new patients
Acclaim-2 is no Longer enrolling new patients. allt Overview of the former trial: Accl aim: 2 Patients with advanced NSCLC whose disease progressed after ‘treatment with Keytruda® : FDA Fast Track Designation Regorsa®in combination with Merck & Co's Keytruda® for NSCLC Phase 2b: Comparing Progressio